Benigne und präinvasive Läsion der Brust

Kathrin Stewen; Susanne Theis; Andrea Teifke; Elke Kohlwes; Annette Hasenburg

doi:10.1055/a-0821-3798

Frauenheilkunde up2date, Table of Contents

Frauenheilkunde up2date 2019; 13(05): 423-439
DOI: 10.1055/a-0821-3798

Allgemeine Gynäkologie

Georg Thieme Verlag KG Stuttgart · New York

Benigne und präinvasive Läsion der Brust

Authors

Kathrin Stewen
Susanne Theis
Andrea Teifke
Elke Kohlwes
Annette Hasenburg

Abstract

All articles of this category

Zahlreiche Läsionen in der Brust sind Differenzialdiagnosen gutartiger Herd- und Tastbefunde sowie bildgebender Zufallsbefunde. Sie können benigne oder prämaligne sein, oder es handelt sich um Vorläufer- oder gar Indikatorläsionen eines Brustkrebses. Entsprechend ihrem heterogenen Erscheinungsbild ist auch die Therapie nicht einheitlich und von Begleitfaktoren abhängig.

Schlüsselwörter

Gutartige Veränderungen der Brust - unklares biologisches Potenzial - B3-Läsionen der Brust - Vorläuferläsionen der Brust - Indikatorläsionen der Brust

Full Text

References

Literatur
1 Griesbaum R, Peters F. Onkologie. Fibroadenom: Diagnostik und Therapie. Geburtsh Frauenheilk 2008; 68: 941-944
2 Dupont WD, Page DL, Parl FF. et al. Long-term risk of breast cancer in women with fibroadenoma. Engl J Med 1994; 331: 10-15
3 McDivitt RW, Stevens JA, Lee NC. et al. Histologic types of benign breast disease and the risk for breast cancer. Cancer 1992; 69: 1408-1414
4 Aktuelle Empfehlungen der AGO Kommission Mamma 2019, aktualisiert 18.3.2019. Im Internet: http://www.ago-online.de/de/infothek-fuer-aerzte/leitlinienempfehlungen/mamma/ Stand: 12.04.2019
5 Bernstein L, Deapen D, Ross RK. The descriptive epidemiology of malignant cystosarcoma phyllodes tumors of the breast. Cancer 1993; 71: 3020-3024
6 MacDonald OK, Lee CM, Tward JD. et al. Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer 2006; 107: 2127-2133
7 Norris HJ, Taylor HB. Relationship of histologic features to behavior of cystosarcoma phyllodes. Analysis of ninety-four cases. Cancer 1967; 20: 2090-2099
8 Golatta M, Harcos A, Junkermann H, Heil J. Benigne Befunde in der Mammasonografie. In: Sohn C, Holzgreve W. Hrsg. Ultraschall in Gynäkologie und Geburtshilfe. Stuttgart: Thieme; 2013: 728-736
9 Bellocq JP, Magro G. Fibroepithelial Tumours. In: Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and female genital Organs. Lyon: IARC Press; 2003: 99-103
10 Wahner-Roedler DL, Sebo TJ, Gisvold JJ. Hamartomas of the breast: clinical, radiologic and pathologic manifestations. Breast J 2001; 7: 101-105
11 Mester J, Simmons RM, Vazquez MF. et al. In situ and infiltrating ductal carcinoma arising in a breast hamartoma. Am J Roentgenol 2000; 175: 64-66
12 Universitätsklinikum Bonn. Humangenetik. Im Internet: http://www.humangenetics.uni-bonn.de/de/beratung/erbliche-tumorerkrankungen/krankheitsbilder/cowden-syndrom Stand: 12.04.2019
13 Wen X, Cheng W. Nonmalignant breast papillary lesions at core-needle biopsy: a meta-analysis of underestimation and influencing factors. Ann Surg Oncol 2013; 20: 94-101
14 S3-Leitlinie Mammakarzinom Version 4.1. 2018. Im Internet: http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/ Stand: 12.04.2019
15 Calhoun BC, Collin LC. Recommendations for excision following core needle biopsy of the breast: a contemporary evaluation of the literature. Histopathology 2016; 68: 138-151
16 Farshid G, Buckley E. Meta-analysis of upgrade rates in 3163 radial scars excised after needle core biopsy diagnosis. Breast Cancer Res Treat 2018; 174: 165-177
17 Bunting DM, Steel JR, Holgate CS. et al. Long term follow-up and risk of breast cancer after a radial scar orcomplex sclerosinglesion has been identified in a benign open breast biopsy. Eur J Surg Oncol 2011; 37: 709-713
18 Boulos FI, Dupont WD, Simpson JF. et al. Histologic associations and long-term cancer risk in columnar cell lesions of the breast: a retrospective cohort and a nested case-control study. Cancer 2008; 113: 2415-2421
19 Calhoun BC, Sobel A, White RL. et al. Management of flat epithelial atypia on breast core biopsy may be individualized based on correlation with imaging studies. Modern Pathology 2015; 28: 670-676
20 Said SM, Visscher DW, Nassar A. et al. Flat epithelial atypia and risk of breast cancer: A Mayo cohort study. Cancer 2015; 121: 1548-1555
21 Andersen JA. Lobular carcinoma in situ. A long-term follow-up in 52 cases. Acta Pathol Microbiol Scand A 1974; 82: 519-533
22 Ottesen GL, Graversen HP, Blichert-Toft M. et al. Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. Am J Surg Pathol 1993; 17: 14-21
23 RKI. Krebs in Deutschland 2011/2012. 2015 2015. Im Internet: http://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2015/krebs_in_deutschland_2015.pdf Stand: 12.04.2019
24 Cuzick J, Sestak I, Cawthorn S. et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 2015; 16: 67-75
25 Cuzick J, Sestak I, Pinder SE. et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results form the UK/ANZ DCIS trial. Lancet Oncol 2010; 12: 21-29
26 Donker M, Litière S, Werutsky G. et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 2013; 31: 4054-4059
27 Wapnir Il. Dignam JJ, Fisher B. et al. Long term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B17 and B24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011; 103: 478-488
28 Warnberg F, Garmo H, Emdin S. et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. J Clin Oncol 2014; 32: 3613-3618
29 Subhedar P, Olcese C, Patil S. et al. Decreasing recurrence rates for ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery over 30 years. Ann Surg Oncol 2015; 22: 3273-3281
30 Kerlikowske K, Molinaro AM, Gauthier ML. Biomarkers expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 2010; 102: 627-637
31 Levine M. Steering Committee on Clinical Practice Guidelines for the Care and treatment of Breast Cancer. Management of ductal carcinoma in situ (summary of the 2001 update). Canadian Med Assoc J 2001; 165: 912-913
32 Page DL, Dupont WD, Rogers LW. et al. Continued local recurrence of carcinoma 15-25 years of diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995; 76: 1197-2000
33 Narod SA, Iqbal J, Giannakeas V. et al. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 2015; 1: 888-896
34 Goodwin A, Parker S, Ghersi D. et al. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev 2013; (11) CD000563
35 Staley H, McCallum I, Bruce J. Postoperative tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis. Breast 2014; 23: 546-551 doi:10.1016/j.breast.2014.06.015
36 Guerrieri-Gonzaga A, Lazzeroni M, Botteri E. et al. Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study. Ann Oncol 2013; 24: 1859-1866